AXSOME THERAPEUTICS INC (AXSM)
US05464T1043 - Common Stock
Noteworthy Friday Option Activity: IRM, BRKR, AXSM
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
Noteworthy Monday Option Activity: LULU, AXSM, FLG
Noteworthy Tuesday Option Activity: TJX, AVAV, AXSM
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript
AXSM earnings call for the period ending September 30, 2024.
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Total 3Q 2024 net product revenue of $104.8 million, representing 81% year-over-year growth Auvelity® 3Q 2024 net product sales of $80.4 million,...
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Yes, bargains can still be found in the stock market.
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
1 Under-the-Radar Biotech Stock to Buy and Hold
It could be an industry giant in the making.
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disorders
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disorders...
Notable Tuesday Option Activity: AXSM, BFH, DBI
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
FDA sets PDUFA action goal date of January 31, 2025
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
FDA sets PDUFA action goal date of January 31, 2025...
Axsome Therapeutics to Participate in Investor Conferences in September
Axsome Therapeutics to Participate in Investor Conferences in September
Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York Wells Fargo Healthcare Conference on September 5 in Boston Baird...
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Notable Monday Option Activity: AXSM, BSX, YOU
Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript
AXSM earnings call for the period ending June 30, 2024.
Why Axsome Therapeutics Stock Is Sinking Today
Investors were unhappy with Axsome's worse-than-expected Q2 loss.
Axsome Plunges On Wide Losses, But Its Biggest Moneymaker Tacks On 135% Growth
The company makes treatments for depression and excessive daytime sleepiness.
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Total 2Q 2024 net product revenue of $87.2 million, representing 87% year-over-year growth Auvelity® 2Q 2024 net product sales of $65.0 million,...
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END